Qian Wang

Qian Wang


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
YLYuliang Li
Yuliang Li
CYChao Yu
Chao Yu
BYBo Yang
Bo Yang
ZLZhirui Liu
Zhirui Liu
PXPeiyuan Xia
Peiyuan Xia
QWQian Wang
Qian Wang

20 May 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
LCLi-Ya Cao
Li-Ya Cao
YZYue Zhao
Yue Zhao
YCYang Chen
Yang Chen
PMPan Ma
Pan Ma
JXJiang-Chuan Xie
Jiang-Chuan Xie
LXLinli Xie
Linli Xie
Chimeric antigen receptor T (CAR-T) cell therapy has undergone vigorous development in recent years, yet it still faces significant challenges and difficulties in its clinical application and further development. A systematic synthesis of global trends in CAR-T clinical trials is essential to identify knowledge gaps, optimize treatment strategies, and guide future research directions. This review analyzed 1,580 CAR-T clinical trials registered at ClinicalTrials.gov as of April 2024, and extracted characteristic data in multiple dimensions, including target specificity, treatment indication, and development stage etc. The transparency of trial outcomes was assessed by validation with articles published in PubMed/Google Scholar. Additionally, it is complemented by investigator surveys assessing to barriers to CAR-T development, prospects, and recommendations.

29 January 2022 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
YLYuliang Li
Yuliang Li
CZChengli Zhang
Chengli Zhang
YHYingjuan He
Yingjuan He
JGJining Gao
Jining Gao
WLWei Li
Wei Li
QWQian Wang
Qian Wang

24 June 2023 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
LCLin Cheng
Lin Cheng
YZYue Zhao
Yue Zhao
ZLZaiming Liang
Zaiming Liang
XYXi You
Xi You
CJChangsheng Jia
Changsheng Jia
FSFengjun Sun
Fengjun Sun
Objective: Plasma trough concentration of voriconazole (VCZ) was associated with its toxicity and efficacy. However, the nonlinear pharmacokinetic characteristics of VCZ make it difficult to determine the relationship between clinical characteristics and its concentration. We intended to present a machine learning (ML)-based method to predict toxic plasma trough concentration of VCZ (>5 & mu;g/mL).Methods: A single center retrospective study was conducted. Three ML algorithms were used to estimate the concentration in adult patients, including random forest (RF), gradient boosting (GB), and extreme gradient boosting (XGBoost). The importance of variables was recognized by the SHapley Additive exPlanations (SHAP) method. In addition, an external validation set was used to validate the robustness of models.Results: A total of 1318 VCZ plasma concentration were included, with 33 variables enrolled in the model. Nine classification models were developed using the RF, GB, and XGBoost algorithms. Most models performed well for both the training set and test set, with an average balanced accuracy (BA) of 0.704 and an average accuracy (ACC) of 0.788. In addition, the average Matthews correlation coefficient value reached 0.484, which indicated the predicted values are meaningful. Based on the average BA and ACC values, the predictive ability of the models can be ranked from best to worst as follows: younger adult models > mixed models > elderly models, and XGBoost models > GBT models > RF models. The SHAP results showed that the top five influencing factors in younger adult patients (<60 years) were albumin, total bile acid (TBA), platelets count, age, and inflammation, while the top five influencing factors in elderly patients were albumin, TBA, aspartate aminotransferase, creatinine, and alanine aminotransferase. Furthermore, the prediction of external validation set for VCZ concentrations verified the high reliability of the models, for the ACC value of 0.822 by the best model.Conclusions: The ML models can be reliable tools for predicting toxic concentration exposure of VCZ. The SHAP results may provide useful guidelines for dosage adjustment of VCZ.

6 January 2023 in Thrombosis Research
Verified
Journal Article
Closed access
YZYue Zhao
Yue Zhao
LCLi-Ya Cao
Li-Ya Cao
YZYing-Xin Zhao
Ying-Xin Zhao
FWFei Wang
Fei Wang
LXLin-Li Xie
Lin-Li Xie
QWQian Wang
Qian Wang

26 August 2022 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
LCLin Cheng
Lin Cheng
PYPu Yao
Pu Yao
HWHongping Wang
Hongping Wang
QYQian Yuan
Qian Yuan
XWXiaowen Wang
Xiaowen Wang
QWQian Wang
Qian Wang
Objective: In this study, the Lactobacillus plantarum HFY15 (LP-HFY15) strain isolated from naturally fermented yak yogurt was investigated. An animal model of lupus nephritis was established by pristane to verify the interventional effect of LP-HFY15 on mouse lupus nephritis by regulating the transforming growth factor-β 1 (TGF-β 1) signaling pathway. Materials and Methods: Indexes in mouse serum and tissues were detected by kits, pathological changes in mouse kidney were observed by hematoxylin-eosin (H&E) staining, and quantitative polymerase chain reaction (qPCR) was used to detect TGF-β 1-related expression in mouse kidney tissue, which further elucidated the mechanism of LP-HFY15. Results: LP-HFY15 decreased the elevation of urinary protein and the levels of interleukin-6 (IL-6), IL-12, tumor necrosis factor alpha (TNF-α), and interferon γ (IFN-γ) in serum and kidney tissue. LP-HFY15 also reduced serum creatinine (SCr), blood urea nitrogen (BUN), total cholesterol (TC), triglyceride (TG), and raised total protein (TP), and albumin (ALB) levels in mice with nephritis. In addition, LP-HFY15 inhibited the positive rate of double-stranded deoxyribonucleic acid (dsDNA) antibodies in mice with nephritis. The observation of H&E sections showed that LP-HFY15 alleviated the glomerulus morphological incompleteness and inflammatory infiltration caused by nephritis. Further results showed that LP-HFY15 downregulated the mRNA expression of TGF-β 1, vascular endothelial growth factor (VEGF), and nuclear factor kappa-B (NF-κB) in the kidneys of lupus nephritis mice, and the expression of inhibitor of NF-κB (IκB-α), copper/zinc superoxide dismutase (Cu/Zn-SOD), and manganese superoxide dismutase (Mn-SOD) was also upregulated. Conclusion: These results indicated that LP-HFY15 plays a significant role in experimental intervention for lupus nephritis. The effect of LP-HFY15 was positively correlated with its concentration, and the effect was similar to that of prednisone at 109 CFU/kg.